Today: 14 March 2026
Subscribe
Browse Category

NYSE:HIMS 23 November 2025 - 13 March 2026

Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health shares traded near $23.82 Friday after a volatile week sparked by its new obesity-drug deal with Novo Nordisk. Under the agreement, Hims will sell FDA-approved Wegovy and Ozempic at Novo’s prices and stop advertising compounded GLP-1 drugs. Analysts warn the shift to branded drugs could hurt margins, with Hims needing far more subscriptions to offset lost profits. The FDA and Eli Lilly have stepped up scrutiny of compounded weight-loss drugs.
13 March 2026
·
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Dow futures rose 46 points premarket Monday while S&P 500 and Nasdaq 100 futures slipped. Kroger jumped 6% after a report naming Greg Foran as incoming CEO. Hims & Hers fell after pulling its $49 weight-loss pill following regulatory pressure. Traders awaited delayed January payrolls data and Friday’s CPI report.
9 February 2026
········
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.
8 February 2026
···
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
7 February 2026
··
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers Health shares fell 2.6% to $22.88 Friday after launching a $49 compounded version of Novo Nordisk’s Wegovy weight-loss pill. Novo called the move “illegal mass compounding” and threatened legal action, while the FDA warned it would act against unapproved copycat drugs. Hims said its pill uses “liposomal technology” to aid absorption but gave no details. Nearly a third of Hims shares are out on loan for short bets.
6 February 2026
·
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims & Hers Health (NYSE: HIMS) closed at about $39–39.3 per share on December 5, 2025, with a market cap near $9 billion. The company authorized a new $250 million share buyback after completing its previous $100 million program. Hims reported nearly 50% year-over-year revenue growth and remains profitable. Shares have swung between $24 and $73 over the past year.
6 December 2025
·
Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health shares closed at $40.02 on December 4, up nearly 8%, following a Q3 revenue jump of 49% to $599 million and guidance for Q4 revenue of $605–625 million. The company announced a $250 million buyback, two acquisitions, and a new chief policy officer. Shares remain well below the 52-week high of $72.98, with short interest elevated and volatility high.
5 December 2025
··
Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers shares jumped about 8% Thursday to $40.19 after announcing a Canada launch, backed by its Livewell acquisition. The company also agreed to buy YourBio Health and recently launched a diagnostics platform with Quest Diagnostics. Market cap stands near $12.8 billion. Short interest remains high, with 67.6 million shares sold short, or about 36% of the float.
4 December 2025
···
1 2

Stock Market Today

  • Q4 Earnings Recap: Astec Leads Heavy Machinery Firms Amid Mixed Sector Results
    March 13, 2026, 9:27 PM EDT. Astec (NASDAQ:ASTE) topped the heavy machinery sector with Q4 revenues rising 11.6% to $400.6 million, beating analyst expectations by 7.1%. The company also surpassed earnings per share (EPS) and EBITDA estimates, reflecting strong operational performance. Despite this, Astec shares fell 8.2% to $53.72 post-earnings. Douglas Dynamics (NYSE:PLOW) reported the fastest revenue growth, up 28.6% to $184.5 million, and exceeded EBITDA and revenue estimates, yet its stock declined 1.6%. In contrast, Alamo (NYSE:ALG) missed revenue targets, with a 3% decline to $373.7 million, pulling shares lower. The sector overall beat revenue forecasts by 3.8%, though average share prices fell 2.8%, affected by economic cycles and interest rate pressures on construction demand.
Go toTop